Index
1 Primary CD56+ NK Cells Market Overview
1.1 Product Overview and Scope of Primary CD56+ NK Cells
1.2 Primary CD56+ NK Cells Segment by Type
1.2.1 Global Primary CD56+ NK Cells Market Value Comparison by Type (2023-2029)
1.2.2 Custom Made
1.2.3 Bulk
1.3 Primary CD56+ NK Cells Segment by Application
1.3.1 Global Primary CD56+ NK Cells Market Value by Application: (2023-2029)
1.3.2 Compound Screening
1.3.3 Immune Function Assay
1.3.4 Drug Discovery
1.3.5 Others
1.4 Global Primary CD56+ NK Cells Market Size Estimates and Forecasts
1.4.1 Global Primary CD56+ NK Cells Revenue 2018-2029
1.4.2 Global Primary CD56+ NK Cells Sales 2018-2029
1.4.3 Global Primary CD56+ NK Cells Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Primary CD56+ NK Cells Market Competition by Manufacturers
2.1 Global Primary CD56+ NK Cells Sales Market Share by Manufacturers (2018-2023)
2.2 Global Primary CD56+ NK Cells Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Primary CD56+ NK Cells Average Price by Manufacturers (2018-2023)
2.4 Global Primary CD56+ NK Cells Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Primary CD56+ NK Cells, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Primary CD56+ NK Cells, Product Type & Application
2.7 Primary CD56+ NK Cells Market Competitive Situation and Trends
2.7.1 Primary CD56+ NK Cells Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Primary CD56+ NK Cells Players Market Share by Revenue
2.7.3 Global Primary CD56+ NK Cells Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Primary CD56+ NK Cells Retrospective Market Scenario by Region
3.1 Global Primary CD56+ NK Cells Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Primary CD56+ NK Cells Global Primary CD56+ NK Cells Sales by Region: 2018-2029
3.2.1 Global Primary CD56+ NK Cells Sales by Region: 2018-2023
3.2.2 Global Primary CD56+ NK Cells Sales by Region: 2024-2029
3.3 Global Primary CD56+ NK Cells Global Primary CD56+ NK Cells Revenue by Region: 2018-2029
3.3.1 Global Primary CD56+ NK Cells Revenue by Region: 2018-2023
3.3.2 Global Primary CD56+ NK Cells Revenue by Region: 2024-2029
3.4 North America Primary CD56+ NK Cells Market Facts & Figures by Country
3.4.1 North America Primary CD56+ NK Cells Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Primary CD56+ NK Cells Sales by Country (2018-2029)
3.4.3 North America Primary CD56+ NK Cells Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Primary CD56+ NK Cells Market Facts & Figures by Country
3.5.1 Europe Primary CD56+ NK Cells Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Primary CD56+ NK Cells Sales by Country (2018-2029)
3.5.3 Europe Primary CD56+ NK Cells Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Primary CD56+ NK Cells Market Facts & Figures by Country
3.6.1 Asia Pacific Primary CD56+ NK Cells Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Primary CD56+ NK Cells Sales by Country (2018-2029)
3.6.3 Asia Pacific Primary CD56+ NK Cells Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Primary CD56+ NK Cells Market Facts & Figures by Country
3.7.1 Latin America Primary CD56+ NK Cells Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Primary CD56+ NK Cells Sales by Country (2018-2029)
3.7.3 Latin America Primary CD56+ NK Cells Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Primary CD56+ NK Cells Market Facts & Figures by Country
3.8.1 Middle East and Africa Primary CD56+ NK Cells Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Primary CD56+ NK Cells Sales by Country (2018-2029)
3.8.3 Middle East and Africa Primary CD56+ NK Cells Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Primary CD56+ NK Cells Sales by Type (2018-2029)
4.1.1 Global Primary CD56+ NK Cells Sales by Type (2018-2023)
4.1.2 Global Primary CD56+ NK Cells Sales by Type (2024-2029)
4.1.3 Global Primary CD56+ NK Cells Sales Market Share by Type (2018-2029)
4.2 Global Primary CD56+ NK Cells Revenue by Type (2018-2029)
4.2.1 Global Primary CD56+ NK Cells Revenue by Type (2018-2023)
4.2.2 Global Primary CD56+ NK Cells Revenue by Type (2024-2029)
4.2.3 Global Primary CD56+ NK Cells Revenue Market Share by Type (2018-2029)
4.3 Global Primary CD56+ NK Cells Price by Type (2018-2029)
5 Segment by Application
5.1 Global Primary CD56+ NK Cells Sales by Application (2018-2029)
5.1.1 Global Primary CD56+ NK Cells Sales by Application (2018-2023)
5.1.2 Global Primary CD56+ NK Cells Sales by Application (2024-2029)
5.1.3 Global Primary CD56+ NK Cells Sales Market Share by Application (2018-2029)
5.2 Global Primary CD56+ NK Cells Revenue by Application (2018-2029)
5.2.1 Global Primary CD56+ NK Cells Revenue by Application (2018-2023)
5.2.2 Global Primary CD56+ NK Cells Revenue by Application (2024-2029)
5.2.3 Global Primary CD56+ NK Cells Revenue Market Share by Application (2018-2029)
5.3 Global Primary CD56+ NK Cells Price by Application (2018-2029)
6 Key Companies Profiled
6.1 PBM
6.1.1 PBM Corporation Information
6.1.2 PBM Description and Business Overview
6.1.3 PBM Primary CD56+ NK Cells Sales, Revenue and Gross Margin (2018-2023)
6.1.4 PBM Primary CD56+ NK Cells Product Portfolio
6.1.5 PBM Recent Developments/Updates
6.2 ATCC
6.2.1 ATCC Corporation Information
6.2.2 ATCC Description and Business Overview
6.2.3 ATCC Primary CD56+ NK Cells Sales, Revenue and Gross Margin (2018-2023)
6.2.4 ATCC Primary CD56+ NK Cells Product Portfolio
6.2.5 ATCC Recent Developments/Updates
6.3 STEMCEITM
6.3.1 STEMCEITM Corporation Information
6.3.2 STEMCEITM Description and Business Overview
6.3.3 STEMCEITM Primary CD56+ NK Cells Sales, Revenue and Gross Margin (2018-2023)
6.3.4 STEMCEITM Primary CD56+ NK Cells Product Portfolio
6.3.5 STEMCEITM Recent Developments/Updates
6.4 Thermo Fisher Scientific
6.4.1 Thermo Fisher Scientific Corporation Information
6.4.2 Thermo Fisher Scientific Description and Business Overview
6.4.3 Thermo Fisher Scientific Primary CD56+ NK Cells Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Thermo Fisher Scientific Primary CD56+ NK Cells Product Portfolio
6.4.5 Thermo Fisher Scientific Recent Developments/Updates
6.5 AllCells
6.5.1 AllCells Corporation Information
6.5.2 AllCells Description and Business Overview
6.5.3 AllCells Primary CD56+ NK Cells Sales, Revenue and Gross Margin (2018-2023)
6.5.4 AllCells Primary CD56+ NK Cells Product Portfolio
6.5.5 AllCells Recent Developments/Updates
6.6 ABM
6.6.1 ABM Corporation Information
6.6.2 ABM Description and Business Overview
6.6.3 ABM Primary CD56+ NK Cells Sales, Revenue and Gross Margin (2018-2023)
6.6.4 ABM Primary CD56+ NK Cells Product Portfolio
6.6.5 ABM Recent Developments/Updates
6.7 3H Biomedical
6.6.1 3H Biomedical Corporation Information
6.6.2 3H Biomedical Description and Business Overview
6.6.3 3H Biomedical Primary CD56+ NK Cells Sales, Revenue and Gross Margin (2018-2023)
6.4.4 3H Biomedical Primary CD56+ NK Cells Product Portfolio
6.7.5 3H Biomedical Recent Developments/Updates
6.8 ProMab Biotechnologies
6.8.1 ProMab Biotechnologies Corporation Information
6.8.2 ProMab Biotechnologies Description and Business Overview
6.8.3 ProMab Biotechnologies Primary CD56+ NK Cells Sales, Revenue and Gross Margin (2018-2023)
6.8.4 ProMab Biotechnologies Primary CD56+ NK Cells Product Portfolio
6.8.5 ProMab Biotechnologies Recent Developments/Updates
6.9 AcceGen
6.9.1 AcceGen Corporation Information
6.9.2 AcceGen Description and Business Overview
6.9.3 AcceGen Primary CD56+ NK Cells Sales, Revenue and Gross Margin (2018-2023)
6.9.4 AcceGen Primary CD56+ NK Cells Product Portfolio
6.9.5 AcceGen Recent Developments/Updates
6.10 AMSBIO
6.10.1 AMSBIO Corporation Information
6.10.2 AMSBIO Description and Business Overview
6.10.3 AMSBIO Primary CD56+ NK Cells Sales, Revenue and Gross Margin (2018-2023)
6.10.4 AMSBIO Primary CD56+ NK Cells Product Portfolio
6.10.5 AMSBIO Recent Developments/Updates
6.11 Clinisciences
6.11.1 Clinisciences Corporation Information
6.11.2 Clinisciences Primary CD56+ NK Cells Description and Business Overview
6.11.3 Clinisciences Primary CD56+ NK Cells Sales, Revenue and Gross Margin (2018-2023)
6.11.4 Clinisciences Primary CD56+ NK Cells Product Portfolio
6.11.5 Clinisciences Recent Developments/Updates
6.12 Creative Bioarray
6.12.1 Creative Bioarray Corporation Information
6.12.2 Creative Bioarray Primary CD56+ NK Cells Description and Business Overview
6.12.3 Creative Bioarray Primary CD56+ NK Cells Sales, Revenue and Gross Margin (2018-2023)
6.12.4 Creative Bioarray Primary CD56+ NK Cells Product Portfolio
6.12.5 Creative Bioarray Recent Developments/Updates
6.13 iCell Bioscience
6.13.1 iCell Bioscience Corporation Information
6.13.2 iCell Bioscience Primary CD56+ NK Cells Description and Business Overview
6.13.3 iCell Bioscience Primary CD56+ NK Cells Sales, Revenue and Gross Margin (2018-2023)
6.13.4 iCell Bioscience Primary CD56+ NK Cells Product Portfolio
6.13.5 iCell Bioscience Recent Developments/Updates
6.14 Shenzhen Kingfocus Biomedical
6.14.1 Shenzhen Kingfocus Biomedical Corporation Information
6.14.2 Shenzhen Kingfocus Biomedical Primary CD56+ NK Cells Description and Business Overview
6.14.3 Shenzhen Kingfocus Biomedical Primary CD56+ NK Cells Sales, Revenue and Gross Margin (2018-2023)
6.14.4 Shenzhen Kingfocus Biomedical Primary CD56+ NK Cells Product Portfolio
6.14.5 Shenzhen Kingfocus Biomedical Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Primary CD56+ NK Cells Industry Chain Analysis
7.2 Primary CD56+ NK Cells Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Primary CD56+ NK Cells Production Mode & Process
7.4 Primary CD56+ NK Cells Sales and Marketing
7.4.1 Primary CD56+ NK Cells Sales Channels
7.4.2 Primary CD56+ NK Cells Distributors
7.5 Primary CD56+ NK Cells Customers
8 Primary CD56+ NK Cells Market Dynamics
8.1 Primary CD56+ NK Cells Industry Trends
8.2 Primary CD56+ NK Cells Market Drivers
8.3 Primary CD56+ NK Cells Market Challenges
8.4 Primary CD56+ NK Cells Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer